SciBac shifts the paradigm on how to treat disease, by creating live biotherapeutics that replace antibiotics. SciBac improves beneficial microorganisms using their novel platform that can quickly transfer useful genetic traits without adding exogenous vectors. The resulting microorganism has all the best traits to target a specific disease, providing more effective and beneficial treatment than antibiotics.

SciBac’s first product targets the nation’s biggest antibiotic resistant threat, Clostridium difficile infection. SciBac’s strains out compete C.difficile by stopping colonization, neutralizing toxins, and directly killing the C.difficile organism. Unlike antibiotics, their product only targets C.difficile, allowing the rest of a patient’s microbiome to thrive, speeding up patient recovery and lowering the risk of recurrence. 

“We are thrilled to be working with TFG and the opportunity to learn from their invaluable insights and experience as we bring our live biotherapeutic products to market.” – Jeanette Mucha, CTO and Co-Founder

Learn more about SciBac:




SciBac's EIR: Ashwin Gulati 

Posted on March 16, 2016 .